Abstract

Monocyte adhesion to the endothelium plays a central role in the progression of endothelial dysfunction and cardiovascular disease (CVD). Epidemiological studies report a relationship between vitamin‐D (VD) deficiency and increased risk of CVD in diabetic patients. This study examines whether or not VD supplementation is beneficial in preventing endothelial dysfunction in diabetes. HUVECs were treated with 1, 25‐(OH)2‐D3 (0–50nM) for 24h, and later exposed to the ketone body acetoacetate (AA; 0, 2, 4, 8mM) or high glucose (HG, 25mM) for 24h. There was an increase in ROS, ICAM‐1 expression, and monocyte adhesion in HUVECs treated with AA or HG. VD (50nM) supplementation lowered ROS (41%, p<0.05), ICAM‐1 (73%, p=0.05) and p‐NFêB (50%, p<0.05) expression, and IL‐8 (16%, p=0.05) and MCP‐1 (41.2%, p<0.001) secretion in HUVECs treated with AA. VD significantly inhibited (37.5%, p=0.05) monocyte adhesion to HUVECs exposed to AA. VD had a similar beneficial effect on HUVECs treated with HG. Apocyanin (NADPH oxidase inhibitor), reduced ROS in HG or AA treated HUVECs. The role of VD in inhibiting NADPH oxidases and ROS is under investigation. This study provides the biochemical mechanism through which VD supplementation can lower ROS, ICAM‐1 expression, monocyte adhesion to the endothelium, and thereby the risk of CVD in diabetes.Grant Funding Source: NIDDK and Office of Dietary Supplements

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.